Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy

Clinical Infectious Diseases

Volumn 48, Issue 9, 2009, Pages 1296-1305

  Geretti, Anna Maria ^a   Harrison, Linda ^b   Green, Hannah ^b   Sabin, Caroline ^a   Hill, Teresa ^a   Fearnhill, Esther ^b   Pillay, Deenan ^a,c   Dunn, David ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DATA BASE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; VIROLOGY; VIRUS LOAD; CLASSIFICATION; COMPARATIVE STUDY; DRUG EFFECT; GENETICS; GENOTYPE; IMMUNOLOGY; MIDDLE AGED; TIME; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; GENOTYPE; GREAT BRITAIN; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 65549129096     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598502     Document Type: Article

References (40)

1. Geretti AM. HIV-1 subtypes: epidemiology and significance for HIV management. Curr Opin Infect Dis 2006; 19:1-7.
2. Descamps D, Chaix ML, Andre P, et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 2005;38:545-552.
3. Monno L, Brindicci G, Lo Caputo S, et al. HIV-1 subtypes and circulating recombinant forms (CRFs) from HIV-infected patients residing in two regions of central and southern Italy. J Med Virol 2005;75: 483-490.
4. Booth CL, Garcia-Diaz AM, Youle MS, Johnson MA, Phillips A, Geretti AM. Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother 2007; 59:517-524.
5. Fox J, Dudaz A, Green H, et al. Epidemiology of non-B clade forms of HIV-1 in MSM in the UK [poster 117]. In: Program and abstracts of the 13th Annual Conference of the British HIV Association (Edinburgh, Scotland). British HIV Association, 2007.
6. Kiwanuka N, Laeyendecker O, Robb M, et al. Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 2008; 197:707-713.
7. Kantor R. Impact of HIV-1 pol diversity on drug resistance and its clinical implications. Curr Opin Infect Dis 2006; 19:594-606.
8. Holguin A, Ramirez de Arellano E, Rivas P, Soriano V. Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes. AIDS Rev 2006; 8:98-107.
9. Kantor R, Katzenstein DA, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005; 2:e112.
10. Calazans A, Brindeiro R, Brindeiro P, et al. Low accumulation ofL90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism. J Infect Dis 2005; 191: 1961-1970.
11. Perno CF, Cozzi-Lepri A, Forbici F, et al. Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed. J Infect Dis 2004; 189:1983-1987.
12. Kinomoto M, Appiah-Opong R, Brandful JA, et al. HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors. Clin Infect Dis 2005;41:243-251.
13. Fleury HJ, Toni T, Lan NT, et al. Susceptibility to antiretroviral drugs of CRF01AE, CRF02AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data. AIDS Res Hum Retroviruses 2006; 22:357-366.
14. Abecasis AB, Deforche K, Bacheler LT, et al. Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02-AG. Antivir Ther 2006; 11:581-9.
15. Alexander CS, Montessori V, Wynhoven B, et al. Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiret- roviral-naive individuals in British Columbia. Antivir Ther 2002;7: 31-35.
16. Frater AJ, Dunn DT, Beardall AJ, et al. Comparative response ofAfrican HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 2002; 16:1139-1146.
17. Atlas A, Granath F, Lindstrom A, Lidman K, Lindback S, Alaeus A. Impact of HIV type 1 genetic subtype on the outcome of antiretroviral therapy. AIDS Res Hum Retroviruses 2005;21:221-227.
18. De Wit S, Boulme R, Poll B, Schmit JC, Clumeck N. Viral load and CD4 cell response to protease inhibitor-containing regimens insubtype B versus non-B treatment-naive HIV-1 patients. AIDS 2004;18: 2330-2331.
19. Bocket L, Cheret A, Deuffic-Burban S, et al. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antivir Ther 2005; 10:247-254.
20. Bannister WP, Ruiz L, Loveday C, et al. HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antivir Ther 2006; 11:707-715.
21. UK Group on Transmitted HIV Drug Resistance. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2005;331:1368-1371.
22. The UK Collaborative HIV Cohort Steering Committee. The creation of a large UK-based multicentre cohort of HIV-infected individuals: the UK Collaborative HIV Cohort (UK CHIC) study. HIV Med 2004;5: 115-124.
23. Sabin C.A, Hill T, Lampe F, et al. Treatment exhaustion ofhighlyactive antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ 2005;330: 695-698.
24. Goldstein H. Multilevel statistical models. In: Kendall's library of statistics 3. London: Edward Arnold, 1995.
25. Cassol E, Page T, Mosam A, et al. Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8. J Infect Dis 2005; 191:324-332.
26. Arroyo MA, Hoelscher M, Sateren W, et al. HIV-1 diversity and prevalence differ between urban and rural areas in the Mbeya region of Tanzania. AIDS 2005; 19:1517-1524.
27. Garrido C, Zahonero N, Fernandes D, et al. Subtype variability, vi- rological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. J Antimicrob Chemother 2008;61:694-698.
28. Rouet F, ChaixML, Nerrienet E, et al. Impact ofHIV-1 geneticdiversity on plasma HIV-1 RNA quantification: usefulness of the Agence Na- tionale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr 2007; 45:380-388.
29. Chohan B, Lang D, Sagar M, et al. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol 2005;79:6528-6531.
30. Marozsan AJ, Moore DM, Lobritz MA, et al. Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J Virol 2005;79: 7121-7134.
31. Aggarwal I, Smith M, Tatt ID, et al. Evidence for onward transmission of HIV-1 non-B subtype strains in the United Kingdom. J Acquir Immune Defic Syndr 2006;41:201-209.
32. Smith CJ, Phillips AN, Hill T, et al. The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific an- tiretroviral drugs in use: results from a multicenter cohort study. J Infect Dis 2005; 192:1387-97.
33. Benzie AA, Bansi LK, Sabin CA, et al. Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. AIDS 2007;21:1423-30.
34. Nellen JF, Wit FW, De Wolf F, Jurriaans S, Lange JM, Prins JM. Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands. J Acquir Immune Defic Syndr 2004; 36:943-950.
35. Kleeberger CA, Buechner J, Palella F, et al. Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study. AIDS 2004; 18:683-688.
36. Li X, Margolick JB, Conover CS, et al. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2005; 38:320-328.
37. Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr 2007; 46:547-554.
38. de Arellano ER, Benito JM, Soriano V, Lopez M, Holguin A. Impact of ethnicity and HIV type 1 subtype on response to first-line antiretroviral therapy. AIDS Res Hum Retroviruses 2007;23:891-894.
39. UK Collaborative Group for HIV and STI Surveillance. Testing times: HIV and other sexually transmitted infections in the United Kingdom. London: Health Protection Agency, Centre for Infections, 2007.
40. British HIV Association. 2005-6 Full results of mortality audit. Available at: http://www.bhiva.org/cms1192339.asp. Accessed 18 December 2008.